At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Cabozantinib (XL184), a Dual Inhibitor of MET and VEGFR, in Patients With Metastatic Refractory Soft Tissue Sarcoma
In Brief
A Phase 2 clinical trial evaluating Cabozantinib for Refractory Soft Tissue Sarcomas. Completed, enrolled 55 participants across 1 site.
Detailed Summary
Background: \- Cabozantinib is a cancer treatment drug that blocks the growth of new blood vessels in tumors. It can also block a chemical on tumor cells that allows the cells to grow. A similar drug, pazopanib, is used to treat types of cancer known as sarcomas. Researchers want to see if cabozantinib can be an effective treatment for types of soft tissue sarcoma that have not responded to earlier treatments. Objectives: \- To test the effectiveness of cabozantinib for soft tissue sarcomas that have not responded to standard treatments. Eligibility: \- Individuals at least 18 years of age who have soft tissue sarcomas that have not responded to standard treatments. Design: * Participants will be screened with a physical exam and medical history. Blood samples will be collected. Imaging studies and other tests will be used to study the tumor before the start of treatment. * Participants will take cabozantinib tablets daily for 28-day cycles of treatment. The tablets should be taken whole on an empty stomach. * Treatment will be monitored with frequent blood tests and imaging studies. * Participants will continue to take cabozantinib for as long as the tumor does not become worse and the side effects are not too severe.
Study Details
Timeline
Interventions
Cabozantinib inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumor growth, metastasis, and angiogenesis, and targets primarily mesenchymal-epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2).